Abstract: The present invention relates to a method and system for introducing one or more exogenous substances into an immune cell. The method comprises the steps of: providing a membrane having a plurality of pores configured to allow the immune cell to pass through, wherein the plurality of pores has an average pore diameter which is no less than an average diameter of the immune cell nucleus and no more than an average diameter of the immune cell, passing a fluid containing the immune cell and the on e or more exogenous substances through the plurality of pores to induce a mechanical stress to the immune cell and facilitate introduction of the one or more exogenous substances into the immune cell, and recirculating the fluid containing the immune cell and the one or more exogenous substances such that the same immune cell passes through the membrane more than once. In some embodiments, the immune cell is T-cells and the exogenous substance is mRNA.

Abstract: Systems and methods for continuous printing of a three-dimensional (3D) object are provided. The system includes a resin tank, an optical image source, a support fluid reservoir and a pumping structure. The resin tank is where the 3D object is printed and includes a print bed to form a base of the 3D object. The optical image source modulates light in accordance with a 3D image to vary a degree and pattern of crosslinking in a photocrosslinkable resin in the resin tank. The support fluid reservoir is in fluid communication with the resin tank and includes a support fluid which is immiscible with the photocrosslinkable resin. And the pumping structure is configured to transfer the support fluid from the support fluid reservoir to the resin tank such that the support fluid rises in the resin tank at a same rate as vertical height of a top of the 3D object as the 3D object is printed on the print bed.

Abstract: We describe a Flt-1 decoy comprising a VEGF binding domain of Flt-1 and a membrane anchoring domain, in which the Flt-1 decoy does not substantially comprise an intracellular domain.

Abstract: The present invention relates to exosomes, loaded with genetic material and methods of producing them and to the use of such exosomes for delivering genetic material in vivo, in particular the use of such exosomes in methods of gene therapy or gene silencing.

Abstract: The present invention relates to an unbiased and simultaneous amplification method for preparing a double-stranded DNA library from a sample of more than one type of nucleic acid. In particular, the present invention provides an unbiased and simultaneous amplification method for preparing a double-stranded DNA library from more than one type of nucleic acid in substantially low amount comparative to non-nucleic acid molecules in the sample within a relatively shorter turnaround time and substantially without any purification step between amplifications and between cDNA preparation and amplification as compared to conventional methods of preparing DNA library.

Abstract: The present invention relates to exosomes, loaded with genetic material and methods of producing them and to the use of such exosomes for delivering genetic material in vivo, in particular the use of such exosomes in methods of gene therapy or gene silencing.

Abstract: Systems and methods for continuous printing of a three-dimensional (3D) object are provided. The system includes a resin tank, an optical image source, a support fluid reservoir and a pumping structure. The resin tank is where the 3D object is printed and includes a print bed to form a base of the 3D object. The optical image source modulates light in accordance with a 3D image to vary a degree and pattern of crosslinking in a photocrosslinkable resin in the resin tank. The support fluid reservoir is in fluid communication with the resin tank and includes a support fluid which is immiscible with the photocrosslinkable resin. And the pumping structure is configured to transfer the support fluid from the support fluid reservoir to the resin tank such that the support fluid rises in the resin tank at a same rate as vertical height of a top of the 3D object as the 3D object is printed on the print bed.

Abstract: The present invention relates to exosomes, loaded with genetic material and methods of producing them and to the use of such exosomes for delivering genetic material in vivo, in particular the use of such exosomes in methods of gene therapy or gene silencing.

Abstract: The present invention relates to exosomes, loaded with genetic material and methods of producing them and to the use of such exosomes for delivering genetic material in vivo, in particular the use of such exosomes in methods of gene therapy or gene silencing.

Abstract: There is provided an attachment configured to detachably couple to a fluid extruding device, the attachment comprising: a membrane having a plurality of pores configured to allow a cell to pass through while inducing a mechanical stress to the cell such that the introduction of one or more substances into the cell is facilitated; and an engaging member for coupling to the outlet of the fluid extruding device such that the membrane is in fluid communication with the outlet of the fluid extruding device, wherein the fluid extruding device is configured to extrude fluid via mechanical actuation.

Abstract: The present invention relates to exosomes, loaded with genetic material and methods of producing them and to the use of such exosomes for delivering genetic material in vivo, in particular the use of such exosomes in methods of gene therapy or gene silencing.

Abstract: The present invention relates to exosomes, loaded with genetic material and methods of producing them and to the use of such exosomes for delivering genetic material in vivo, in particular the use of such exosomes in methods of gene therapy or gene silencing.

Abstract: The present invention relates to exosomes, loaded with genetic material and methods of producing them and to the use of such exosomes for delivering genetic material in vivo, in particular the use of such exosomes in methods of gene therapy or gene silencing.

Abstract: The present invention relates to exosomes, loaded with genetic material and methods of producing them and to the use of such exosomes for delivering genetic material in vivo, in particular the use of such exosomes in methods of gene therapy or gene silencing.

Abstract: The present invention relates to an isolated mirtron capable of binding a target nucleic acid, wherein the isolated mirtron comprises: a) a stem loop structure comprising a 5? splice site, b) a tail sequence comprising a 3? splice site and a polypyrimidine-comprising sequence, and c) a branch point sequence. Further, the present invention relates to vectors and pharmaceutical compositions comprising such mirtrons as well as methods of treating a disease comprising administering such pharmaceutical compositions.

Abstract: There is provided a compound comprising at least two ligands that are individually coupled to a linker, wherein each ligand is independently selected from the group consisting of a substituted benzylguanine derivative, a substituted benzylcytosine derivative, a haloalkyl moiety, a drug, a peptide, a hormone, an inorganic compound and a protein. The compound may be part of an oligomer. The compound may be employed in a method of dimerizing a pair of proteins, which may alter a biological function in a cell. There is also provided a method of forming the compound.

Abstract: The present invention relates to exosomes, loaded with genetic material and methods of producing them and to the use of such exosomes for delivering genetic material in vivo, in particular the use of such exosomes in methods of gene therapy or gene silencing.

Abstract: The present invention relates to exosomes, loaded with genetic material and methods of producing them and to the use of such exosomes for delivering genetic material in vivo, in particular the use of such exosomes in methods of gene therapy or gene silencing.

Abstract: The invention provides a mirtron or a gene capable of expressing a mirtron for use in modifying the expression of a target gene in a mammalian cell to prevent or treat a disease, the sequence of the mirtron comprising: (i) a 5? splice site; (ii) a 3? splice site; (iii) a branch-point recognition sequence; (iv) a 3? polypyrimidine tract greater than 15 nucleotides in length; and (v) an antisense sequence that is at least partially complementary to a sequence in the target gene.